ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Ellagic Acid Enhances RSL3-Induced Ferroptosis by Inhibiting the Nrf2/HO-1 Signaling Pathway in Pancreatic Ductal Adenocarcinoma.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) exhibits profound therapeutic resistance due to redox adaptation, particularly through Nrf2/HO-1 pathway activation. Ferroptosis induction via GPX4 inhibitors (e.g., RSL3) is promising but limited by adaptive antioxidant responses. Ellagic acid (EA), a natural polyphenol, may overcome this resistance, yet its role in modulating ferroptosis remains unexplored. In vitro studies used KRAS-mutant and KRAS wild-type PDAC cell lines (PANC-1, BxPC-3) treated with EA, RSL3, or both. Ferroptosis markers (iron, lipid ROS, MDA, GPX4), viability assays, and pathway analyses (Keap1/Nrf2/HO-1, p38 MAPK) were evaluated. In vivo, antitumor efficacy was assessed in PANC-1 xenografts. EA synergized with RSL3, reducing viability in PDAC cells (p < 0.001) and suppressing tumor growth in vivo (p < 0.001). Combination therapy amplified ferroptotic markers as increased intracellular iron, MDA, and lipid ROS, versus RSL3 alone, while GPX4 expression decreased. Ferroptosis specificity was confirmed via Fer-1 rescue. Mechanistically, EA activated p38 MAPK, suppressing Nrf2 nuclear translocation and HO-1 expression. Keap1 upregulation further enhanced Nrf2 degradation. In vivo, EA + RSL3 downregulated Nrf2/HO-1 and elevated phospho-p38 in tumors along with the induction of ferroptosis. EA potentiates RSL3-induced ferroptosis in PDAC by disrupting the p38/Nrf2/HO-1 axis and elevating Keap1. This natural compound-based strategy overcomes redox-driven resistance, offering a translatable approach for PDAC models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.